Ordinary Reweighting | RBC Biotech Opportunities Index Series 2 | Effective Date 3rd July 2023
In the ordinary reweighting, the following index composition will be implemented effective open 03.07.2023:
| ABBVIE INC |
| AGIOS PHARMACEUTICALS INC |
| ALNYLAM PHARMACEUTICALS INC |
| AMGEN INC |
| BIOGEN INC |
| ELI LILLY & CO |
| GILEAD SCIENCES INC |
| INCYTE CORP |
| INTRA-CELLULAR THERAPIES INC |
| KARUNA THERAPEUTICS INC |
| PACIRA BIOSCIENCES INC |
| SAREPTA THERAPEUTICS INC |
| SEAGEN INC |
| XENON PHARMACEUTICALS INC |